logo
When Should You Buy ManpowerGroup Inc. (NYSE:MAN)?

When Should You Buy ManpowerGroup Inc. (NYSE:MAN)?

Yahoo7 days ago

ManpowerGroup Inc. (NYSE:MAN), might not be a large cap stock, but it saw significant share price movement during recent months on the NYSE, rising to highs of US$62.66 and falling to the lows of US$38.37. Some share price movements can give investors a better opportunity to enter into the stock, and potentially buy at a lower price. A question to answer is whether ManpowerGroup's current trading price of US$42.07 reflective of the actual value of the small-cap? Or is it currently undervalued, providing us with the opportunity to buy? Let's take a look at ManpowerGroup's outlook and value based on the most recent financial data to see if there are any catalysts for a price change.
We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.
Great news for investors – ManpowerGroup is still trading at a fairly cheap price according to our price multiple model, where we compare the company's price-to-earnings ratio to the industry average. We've used the price-to-earnings ratio in this instance because there's not enough visibility to forecast its cash flows. The stock's ratio of 17.54x is currently well-below the industry average of 22.53x, meaning that it is trading at a cheaper price relative to its peers. However, given that ManpowerGroup's share is fairly volatile (i.e. its price movements are magnified relative to the rest of the market) this could mean the price can sink lower, giving us another chance to buy in the future. This is based on its high beta, which is a good indicator for share price volatility.
See our latest analysis for ManpowerGroup
Investors looking for growth in their portfolio may want to consider the prospects of a company before buying its shares. Although value investors would argue that it's the intrinsic value relative to the price that matter the most, a more compelling investment thesis would be high growth potential at a cheap price. With profit expected to grow by 88% over the next couple of years, the future seems bright for ManpowerGroup. It looks like higher cash flow is on the cards for the stock, which should feed into a higher share valuation.
Are you a shareholder? Since MAN is currently trading below the industry PE ratio, it may be a great time to increase your holdings in the stock. With a positive profit outlook on the horizon, it seems like this growth has not yet been fully factored into the share price. However, there are also other factors such as capital structure to consider, which could explain the current price multiple.
Are you a potential investor? If you've been keeping an eye on MAN for a while, now might be the time to make a leap. Its prosperous future profit outlook isn't fully reflected in the current share price yet, which means it's not too late to buy MAN. But before you make any investment decisions, consider other factors such as the track record of its management team, in order to make a well-informed assessment.
So while earnings quality is important, it's equally important to consider the risks facing ManpowerGroup at this point in time. Every company has risks, and we've spotted 2 warning signs for ManpowerGroup (of which 1 is concerning!) you should know about.
If you are no longer interested in ManpowerGroup, you can use our free platform to see our list of over 50 other stocks with a high growth potential.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Swiss Growth Revised Up on US Export Surge Before Trump Tariffs
Swiss Growth Revised Up on US Export Surge Before Trump Tariffs

Bloomberg

time19 minutes ago

  • Bloomberg

Swiss Growth Revised Up on US Export Surge Before Trump Tariffs

Switzerland's growth spurt into 2025 was even more pronounced than initially estimated, with the economy expanding at the fastest pace in two years. Before an anticipated hit from US tariffs, gross domestic product adjusted for large sport events increased 0.8% in the first quarter, the government said Monday. That's up from the 0.7% reported in a preliminary reading and more than the revised 0.6% recorded between October and December.

Tom Cruise's Final ‘Mission Impossible' Tops China Box Office
Tom Cruise's Final ‘Mission Impossible' Tops China Box Office

Bloomberg

timean hour ago

  • Bloomberg

Tom Cruise's Final ‘Mission Impossible' Tops China Box Office

Mission: Impossible – The Final Reckoning posted the biggest opening for a US film in the country this year, defying trade and geopolitical tensions between Washington and Beijing. Paramount Global 's eighth installment in the action franchise earned $25.2 million across 11,847 locations in China during the opening weekend, the studio said in a statement. The film is likely to become the top-performing US release in the country for 2025, with Warner Bros Entertainment Inc. 's A Minecraft Movie so far holding the lead with about $29 million since its April 4 debut, according to ticketing platform Maoyan.

Nxera Pharma achieves development milestone in collaboration with Eli Lilly
Nxera Pharma achieves development milestone in collaboration with Eli Lilly

Business Insider

timean hour ago

  • Business Insider

Nxera Pharma achieves development milestone in collaboration with Eli Lilly

Nxera Pharma announces that it has achieved a development milestone under its multi-target collaboration and license agreement with Eli Lilly (LLY) and Company targeting diabetes and metabolic diseases, resulting in a payment to Nxera. The payment amount is undisclosed under the agreement with Lilly. However, Nxera makes this announcement in accordance with the timely disclosure requirements as the achievement of the milestone represents significant progress in research and development for Nxera. Nxera expects to receive the milestone payment in the third quarter of the fiscal year ending December 2025. Under the terms of the agreement, Nxera is eligible to receive development and commercial milestones totalling up to US$694 million, plus tiered royalties on global sales. Confident Investing Starts Here:

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store